Table 3. Relationship among ET-1, ETAR, and ETBR positive tumours and clinical/biological characteristics of breast carcinomas prior to neoadjuvant chemotherapy.
| ET-1 positive (n=39) | P | ETAR-positive (n=40) | P | ETBR-positive (n=39) | P | |
|---|---|---|---|---|---|---|
| T | ||||||
| T2 | 19/34 (55.9%) | 0.232 | 11/35 (31.4%) | 0.190 | 12/34 (35.3%) | 0.414 |
| T3 | 3/3 (100%) | 2/3 (66.7%) | 1/3 (33.3%) | |||
| T4 | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | |||
| Missing | 1 | 1 | 1 | |||
| N | ||||||
| N0 | 12/24 (50%) | 0.082 | 7/24 (29.2%) | 0.391 | 7/22 (31.8%) | 0.715 |
| N+ | 11/14 (78.6%) | 6/14 (42.9%) | 6/16 (37.5%) | |||
| Missing | 1 | 2 | 1 | |||
| Ga | ||||||
| G1 | — | 0.281 | — | 0.436 | 1/1 (100%) | 0.157 |
| G2 | 5/10 (50%) | 2/10 (20%) | 2/11 (18.2%) | |||
| G3 | 15/22 (68.2%) | 9/23 (39.1%) | 9/21 (42.9%) | |||
| Missing | 7 | 7 | 6 | |||
a
Grading of surgical resection specimens postchemotherapy.